Katie Peng Sells 5,446 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Katie Peng sold 5,446 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $293,430.48. Following the completion of the sale, the director owned 34,301 shares of the company’s stock, valued at approximately $1,848,137.88. This represents a 13.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Performance

SRRK stock traded up $0.48 on Monday, hitting $55.36. The company’s stock had a trading volume of 1,182,357 shares, compared to its average volume of 1,407,918. Scholar Rock Holding Corporation has a 1 year low of $27.07 and a 1 year high of $56.54. The stock has a market cap of $6.63 billion, a price-to-earnings ratio of -15.42 and a beta of 0.67. The firm has a 50 day moving average of $48.43 and a two-hundred day moving average of $46.59. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the prior year, the firm posted ($0.67) earnings per share. Equities analysts predict that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors have recently added to or reduced their stakes in the company. Redmile Group LLC increased its position in Scholar Rock by 73.7% during the 1st quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock worth $445,715,000 after purchasing an additional 3,845,775 shares in the last quarter. Orbis Allan Gray Ltd increased its stake in Scholar Rock by 1,034.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock worth $151,044,000 after buying an additional 3,126,677 shares during the period. Wellington Management Group LLP lifted its holdings in Scholar Rock by 124.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after buying an additional 2,521,022 shares in the last quarter. Holocene Advisors LP acquired a new stake in shares of Scholar Rock during the third quarter valued at about $91,670,000. Finally, Norges Bank acquired a new position in shares of Scholar Rock in the fourth quarter worth about $91,603,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on SRRK. Barclays boosted their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. HC Wainwright upped their target price on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a report on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. Wedbush lifted their price objective on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. Finally, Canaccord Genuity Group began coverage on Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price target for the company. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and a consensus price target of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).